Kerelakes DJ, Obenchain RL et al. Abciximab provides cost-effective survival
advantage in high-volume interventional practice. Am. Heart J. 140:603-10;
Obenchain RL. Resampling and multiplicity in cost-effectiveness inference.
J. Biopharmaecutical Statistics. 9(4), 563-582, 1999.
Obenchain RL et al. Bootstrap analyses of cost effectiveness in antidepressant
pharmacotherapy. PharmacoEconomics. 11(5):464-472, 1997.
AH, O’Brien BJ, and Blackhouse G. Thinking
Outside the Box: Recent Advances in the Analysis and Presentation of Uncertainty
in Cost-Effectiveness Studies. Annual Rev. Public Health.
Nixon RM et al. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.
Health Economics. 19:316-333, 2010.
Kim N. et al. An economic analysis of usual care and acupuncture collaborative treatment on chronic low back pain: a Markov decision analysis.
BMC Complementary and Alternative Med. 10:74, 2010.